Skip to main content
Aelis Farma logo

Aelis Farma — Investor Relations & Filings

Ticker · AELIS ISIN · FR0014007ZB4 LEI · 8945008D5R6WV7EXRN47 PA Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2026-05-13 Proxy Solicitation & In…
Country FR France
Listing PA AELIS

About Aelis Farma

https://www.aelisfarma.com

Aelis Farma is a clinical-stage biopharmaceutical company that discovers and develops treatments for brain and central nervous system (CNS) disorders. The company has created a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary mechanism is designed to selectively inhibit the pathological signaling of the CB1 receptor, which is implicated in various brain diseases, while preserving its normal physiological functions and avoiding adverse effects associated with previous CB1-targeting drugs. The company's lead drug candidate, AEF0117, is in development for the treatment of Cannabis Use Disorder (CUD). Its second candidate, AEF0217, is being investigated for the treatment of cognitive deficits, including those associated with Down syndrome.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Proxy Solicitation & Information Statement Classification · 82% confidence The document is a press release announcing the convocation of the mixed Annual General Meeting on June 3, 2026, detailing the agenda, resolutions, how to participate and vote (in person, by proxy, or by correspondence), where to find preparatory materials, and electronic participation arrangements. It is pre‐meeting material sent to shareholders to provide information and solicit their votes, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-13 French
Inside Information / Other news releases
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a press release providing notice of the Combined General Meeting, detailing where shareholders can find the agenda, draft resolutions, and voting procedures, and how to submit proxies or vote by mail. It is not the meeting’s results nor a financial report, nor simply a publication announcement of a report. It is an information and solicitation of votes for a shareholder meeting, which corresponds to our Proxy Solicitation & Information Statement category.
2026-05-13 English
Inside Information / Other news releases
Report Publication Announcement Classification · 92% confidence The document is a press release announcing the publication and availability of Aelis Farma’s 2025 Universal Registration Document (URD) filed with the AMF. It does not contain the full report contents but simply directs investors to download it from the company and AMF websites. Under the “Menu vs Meal” rule, this makes it a Report Publication Announcement (RPA) rather than the report itself.
2026-04-24 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 90% confidence The document is a press release (“Communiqué de presse”) announcing the availability of Aelis Farma’s Universal Registration Document 2025 (including the annual financial report, auditors’ reports, and ESG information) filed with the AMF. It invites investors to consult and download the report on the company’s and AMF’s websites. It is not the report itself but an announcement of its publication. Under our taxonomy, this corresponds to a Report Publication Announcement (RPA).
2026-04-24 French
Document d'Enregistrement Universel 2025
Annual Report Classification · 100% confidence The document is a 'Document d’Enregistrement Universel' (Universal Registration Document), which is the French regulatory equivalent of an Annual Report (10-K). It contains comprehensive financial statements, management reports, governance details, and risk factors for the fiscal year 2025. It is a full-length report, not an announcement or a summary, and thus fits the definition of an Annual Report. FY 2025
2026-04-23 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 82% confidence The document is a corporate press release announcing that Aelis Farma has obtained a non-dilutive government grant of €458k under the France 2030 innovation program to fund its R&D programs. It does not present financial results, governance materials, or regulatory filings, nor does it announce share issues, M&A, or dividends. It constitutes an update on the company’s financing activities (capital/financing update). Therefore, it best fits the Capital/Financing Update category (CAP).
2026-04-07 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.